Rifasutenizol is an investigational new drug developed by TenNor Therapeutics, primarily aimed at treating Helicobacter pylori infections. It is a novel multi-targeting small molecule that functions as a bacterial DNA-directed RNA polymerase inhibitor. This drug has been granted Qualified Infectious Disease Product and Fast Track designations by the U.S. FDA.
References